Chiasma (CHMA) News Today → How Biden has already won 2024 (From Porter & Company) (Ad) Free CHMA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative October 29, 2023 | thestreet.comChiasma Craters on FDA Drug RejectionOctober 6, 2022 | globenewswire.comOrphan Drugs Market Size to Hit USD 340.84 Billion by 2027 - GlobeNewswireSeptember 28, 2022 | businesswire.comIronshore Announces Executive Appointments and Strengthening of the Global Business Management Team - Business WireSeptember 16, 2022 | marketscreener.comCHMP adopts positive opinion for Mycapssa® for the treatment of Acromegaly - Marketscreener.comSeptember 16, 2022 | streetinsider.comAmryt (AMYT) Receives Positive CHMP Opinion for Mycapssa - StreetInsider.comSeptember 7, 2022 | uk.finance.yahoo.comAmryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022 - Yahoo Finance UKAugust 12, 2022 | gurufocus.comMPM ASSET MANAGEMENT LLC Buys - GuruFocus.comAugust 4, 2022 | globenewswire.comAmryt Reports Record Q2 2022 Results - GlobeNewswireJuly 12, 2022 | businesswire.comSpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer - Business WireJuly 12, 2022 | finance.yahoo.comSpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer - Yahoo FinanceJune 20, 2022 | finance.yahoo.comGlobal Food Allergy Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight - Yahoo FinanceJune 18, 2022 | gurufocus.comAmryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022 - GuruFocus.comJune 16, 2022 | finance.yahoo.comAt 10.4% CAGR, Global Oral Proteins and Peptides Market Size & Share to Surpass USD 8.42 Billion by 2028 | Industry Trends, Growth, Value, Opportunities, Statistics, Analysis & Forecast Report by Zion Market Research - Yahoo FinanceJune 15, 2022 | globenewswire.comThe oral proteins and peptides market is anticipated to grow at a CAGR of 20%, during 2022-2032, claims Roots Analysis - GlobeNewswireJune 15, 2022 | finance.yahoo.comThe oral proteins and peptides market is anticipated to grow at a CAGR of 20%, during 2022-2032, claims Roots Analysis - Yahoo FinanceJune 8, 2022 | finance.yahoo.comAmryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022 - Yahoo FinanceMay 13, 2022 | gurufocus.comTop 5 1st Quarter Trades of MPM ASSET MANAGEMENT LLC - GuruFocus.comMay 6, 2022 | financialpost.comAmryt Reports Record Q1 2022 Results - Financial PostMay 4, 2022 | globenewswire.comAmryt Reports Record Q1 2022 Results - GlobeNewswireMay 4, 2022 | stockhouse.com2022-05-04 | NDAQ:AMYT | Press Release | Amryt Pharma plc - StockhouseMarch 21, 2022 | benzinga.comInsights on the Oral Proteins and Peptides Global Market to 2032 - Key Drivers and Challenges - Benzinga - BenzingaMarch 16, 2022 | globenewswire.comGlobal Oral Proteins and Peptides Market to 2032 - by - GlobeNewswireMarch 11, 2022 | streetinsider.comAmryt (AMYT) Reports FY Revenues of $222.5M, Growth of 22% - StreetInsider.comMarch 9, 2022 | globenewswire.comAmryt Announces 22% growth in FY 2021 Revenues to $222.5M - GlobeNewswireFebruary 28, 2022 | prnewswire.comWarm Autoimmune Hemolytic Anemia Market is Expected to Witness Growth at an Accelerated CAGR of 14.7% in the 7MM for the Study Period 2018-30, Assesses DelveInsight - PRNewswireFebruary 8, 2022 | businesswire.comGlobal Thermostable Vaccines and Thermostable Biologics Market to 2035 - by Type of Molecule, Target Indications, Type of Therapy, Key Players and Region - ResearchAndMarkets.com - Business WireJanuary 31, 2022 | prnewswire.comFood Allergy Market Anticipated to Witness Massive Growth with a Tremendous CAGR of 13.5% in the 7MM for the Study Period of 2018-30 | DelveInsight - PRNewswireJanuary 31, 2022 | streetinsider.comForm 424B3 Amryt Pharma plc - StreetInsider.comJanuary 12, 2022 | financialpost.comAmryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management of Acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide - Financial PostJanuary 11, 2022 | morningstar.co.ukIN BRIEF: Amryt Pharma delists from AIM as trading shifts to New York - MorningstarJanuary 7, 2022 | fortune.comVaccine mandates, inflation and remote workforces—here’s what mattered to CFOs this week - FortuneJanuary 5, 2022 | stockhouse.comThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients - StockhouseJanuary 5, 2022 | streetinsider.com4D pharma appoints John Doyle as Chief Financial Officer - StreetInsider.comJanuary 4, 2022 | fortune.comAre you prepared for what the Supreme Court has to say on vaccine mandates? - FortuneJanuary 4, 2022 | finance.yahoo.comThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients - Yahoo FinanceDecember 24, 2021 | bizjournals.comTBJ Plus: New CEO takes helm for Aerie Pharmaceuticals; $1.5B Novartis deal has Durham link; Thermo Fisher name rises in Wilmington - Triangle Business Journal - Triangle Business JournalDecember 22, 2021 | finance.yahoo.comVersantis Appoints Mark Fitzpatrick, Seasoned Biotech Executive, as its New CEO - Yahoo FinanceDecember 22, 2021 | seekingalpha.comNeuroSense: Advancing Generic Combos In Neurodegenerative Diseases - Seeking AlphaDecember 4, 2021 | streetinsider.comVenatorx Pharmaceuticals Names Scott McConnell, Pharm.D. as Vice President, Medical Affairs - StreetInsider.comDecember 2, 2021 | businesswire.comVenatorx Pharmaceuticals Names Scott McConnell, Pharm.D. as Vice President, Medical Affairs - Business WireNovember 15, 2021 | finance.yahoo.comCatamaran Bio Announces Appointment of Tara Place as Vice President, Human Resources and Organizational Effectiveness - Yahoo FinanceNovember 7, 2021 | seekingalpha.comAmryt Pharma (AMYT) CEO Dr. Joe Wiley on Q3 2021 Results - Earnings Call Transcript - Seeking AlphaNovember 3, 2021 | globenewswire.comAmryt Reports Strong Q3 2021 Results - GlobeNewswireNovember 3, 2021 | marketscreener.comAmryt Reports Strong Q3 2021 Results - Form 6-K - Marketscreener.comNovember 3, 2021 | finance.yahoo.comAmryt Reports Strong Q3 2021 Results - Yahoo FinanceSeptember 29, 2021 | finance.yahoo.comNeuroSense Therapeutics announces the appointment of Mark Leuchtenberger as Chairman of the Board - Yahoo FinanceSeptember 14, 2021 | morningstar.co.ukIN BRIEF: Amryt Pharma ups guidance again after Chiasma acquisition - MorningstarSeptember 14, 2021 | lse.co.ukIN BRIEF: Amryt Pharma ups guidance again after Chiasma acquisition | Financial News - London South EastSeptember 13, 2021 | marketwatch.comAmryt Pharma Raises 2021 Revenue Guidance - MarketWatchSeptember 13, 2021 | finance.yahoo.comAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M - Yahoo Finance Get Chiasma News Delivered to You Automatically Sign up to receive the latest news and ratings for CHMA and its competitors with MarketBeat's FREE daily newsletter. Email Address How Biden has already won 2024 (Ad)Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that will forever enshrine Obama’s destructive, Marxist vision for America… A plot that could hand him and his allies near-total control over the government, your way of life, and your future. Click here to watch this now before it’s too late. CHMA Media Mentions By Week CHMA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CHMA News Sentiment▼0.460.42▲Average Medical News Sentiment CHMA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CHMA Articles This Week▼00▲CHMA Articles Average Week Get Chiasma News Delivered to You Automatically Sign up to receive the latest news and ratings for CHMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Merrimack Pharmaceuticals News Veru News Werewolf Therapeutics News Conduit Pharmaceuticals News Eliem Therapeutics News Ovid Therapeutics News Trevi Therapeutics News Zevra Therapeutics News Generation Bio News Puma Biotechnology News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CHMA) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBill Gates is all about this tiny $2 stockTimothy SykesThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsUrgent Nvidia WarningAltimetryCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chiasma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
